Carcinoma hepatocelular

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Goutté, 2017, Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country, J Hepatol, 66, 537, 10.1016/j.jhep.2016.10.015 Rosa I, Denis J, Renard P. A French multicentric longitudinal descriptive study of hepatocellular carcinoma management (The CHANG Cohort). EASL. 2010 [Abstract 586]. El-Serag, 2011, Hepatocellular carcinoma, N Engl J Med, 365, 1118, 10.1056/NEJMra1001683 Yang, 2014, Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis, Cancer, 120, 3707, 10.1002/cncr.28912 Flemming, 2014, Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model, Cancer, 120, 3485, 10.1002/cncr.28832 Zucman-Rossi, 2015, Genetic landscape and biomarkers of hepatocellular carcinoma, Gastroenterology, 149, 1226, 10.1053/j.gastro.2015.05.061 Moudgil, 2013, A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses, J Environ Pathol Toxicol Oncol, 32, 165, 10.1615/JEnvironPatholToxicolOncol.2013007166 Liu, 2012, Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis, Eur J Cancer, 48, 2125, 10.1016/j.ejca.2012.02.009 Nahon, 2017, Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications, Gastroenterology, 152, 142, 10.1053/j.gastro.2016.09.009 Turati, 2013, Metabolic syndrome and hepatocellular carcinoma risk, Br J Cancer, 108, 222, 10.1038/bjc.2012.492 Welzel, 2013, Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States, Am J Gastroenterol, 108, 1314, 10.1038/ajg.2013.160 Piscaglia, 2016, Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study, Hepatology, 63, 827, 10.1002/hep.28368 Wong, 2000, Estimating future hepatitis C morbidity, mortality, and costs in the United States, Am J Public Health, 90, 1562, 10.2105/AJPH.90.10.1562 Van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878 Nakagawa, 2012, Inflammation and stress related signaling pathways in hepatocarcinogenesis, World J Gastroenterol, 18, 4071, 10.3748/wjg.v18.i31.4071 Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038/nrc1934 Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734 European Association for Study of Liver, 2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, Eur J Cancer, 48, 599, 10.1016/j.ejca.2011.12.021 Blanc JF, Barbare JC, Boige V, Boudjema K, Créhange G, Decaens T, et al. « Carcinome hépatocellulaire ». Thésaurus national de cancérologie digestive, 2015. Colecchia, 2011, Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment, J Hepatol, 54, 300, 10.1016/j.jhep.2010.06.037 Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Colli, 2006, Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review, Am J Gastroenterol, 101, 513, 10.1111/j.1572-0241.2006.00467.x Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Liver Transplantation French Study Group, Gastroenterology, 143, 986, 10.1053/j.gastro.2012.05.052 Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122 Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104 Lim, 2012, Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria, Br J Surg, 99, 1622, 10.1002/bjs.8915 Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016/S0168-8278(02)00360-4 Hocquelet, 2016, No-touch multibipolar radiofrequency ablation: the new standard ablative technique for hepatocellular carcinoma 5 cm or smaller?, Radiology, 281, 975, 10.1148/radiol.2016160774 Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008 Song, 2012, Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma, World J Gastroenterol, 18, 3215 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Bruix, 2017, RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9 Cheng, 2017, Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC), J Clin Oncol, 35 El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2